The role of thrombopoietin receptor agonists in reducing complications of chemotherapy-induced thrombocytopenia in patients with hematologic malignancies: review and single-center experience

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Chemotherapy-induced thrombocytopenia (CIT) is one of the most common and clinically significant complications of anticancer therapy. It limits the ability to maintain planned chemotherapy dose intensity, increases the risk of hemorrhagic complications, and leads to a higher demand for platelet transfusions. Given the limited efficacy and availability of transfusion support, the development of pharmacological approaches for CIT management is of high clinical relevance. Thrombopoietin receptor agonists, including avatrombopag, represent a promising strategy in supportive cancer care.

Aim. To evaluate the efficacy and clinical relevance of prophylactic avatrombopag use in patients with chemotherapy-induced thrombocytopenia.

Materials and methods. This observational study included 9 patients (4 males and 5 females) with oncological diseases who developed thrombocytopenia < 100 × 109/L after a previous chemotherapy cycle. The median age was 52 years (range 27–68). Avatrombopag was administered prophylactically after completion of chemotherapy at a dose of 40 mg/day (20 mg twice daily) for 5 or 10 days, depending on the severity of thrombocytopenia. The following parameters were analyzed: nadir platelet count during the inter-cycle period, incidence of hemorrhagic events, requirement for platelet transfusions, and duration of delay of the subsequent chemotherapy cycle.

Results. During avatrombopag administration, the median nadir platelet count remained unchanged at 10 × 109/L; however, a marked increase up to 79 × 109/L was observed in some patients. The incidence of hemorrhagic complications decreased from 55 to 11 %. The median number of platelet transfusions was reduced from 3 to 2 units. A significant reduction in chemotherapy delays was observed, with the median delay decreasing from 11 to 0 days. No avatrombopag-related adverse events were reported.

Conclusion. Prophylactic use of avatrombopag in patients with chemotherapy-induced thrombocytopenia was associated with a reduced incidence of bleeding complications, decreased need for platelet transfusions, and fewer delays in subsequent chemotherapy cycles. Despite the limited sample size, these findings support the clinical value of avatrombopag as a supportive therapy and warrant further prospective studies.

About the authors

A. V. Podenok

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Author for correspondence.
Email: matchamomilla@gmail.com
ORCID iD: 0009-0007-0829-871X
Russian Federation, 4 Koroleva St., Obninsk 249031

D. A. Manaenkov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Email: matchamomilla@gmail.com
ORCID iD: 0009-0007-9269-7405
Russian Federation, 4 Koroleva St., Obninsk 249031

N. A. Falaleeva

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Obninsk Institute for Nuclear Power Engineering – branch of the National Research Nuclear University MEPHI

Email: matchamomilla@gmail.com
ORCID iD: 0000-0002-0023-4216
Russian Federation, 4 Koroleva St., Obninsk 249031; 1 Studgorodok, 249039 Obninsk

V. A. Shuvaev

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Obninsk Institute for Nuclear Power Engineering – branch of the National Research Nuclear University MEPHI; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: matchamomilla@gmail.com
ORCID iD: 0000-0003-3536-0770
Russian Federation, 4 Koroleva St., Obninsk 249031; 1 Studgorodok, 249039 Obninsk; Build. 1, 2/1 Barrikadnaya St., Moscow 125993

A. A. Vovchenko

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Email: matchamomilla@gmail.com
ORCID iD: 0009-0009-6911-3322
Russian Federation, 4 Koroleva St., Obninsk 249031

References

  1. Al-Samkari H., Soff G.A. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. Expert Rev Hematol 2021;14(5):437–48. doi: 10.1080/17474086.2021.1924053
  2. Hitron A., Steinke D., Sutphin S. et al. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J Oncol Pharm Pract 2011;17(4):312–9. doi: 10.1177/1078155210380293
  3. Wu Y., Aravind S., Ranganathan G. et al. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000–2007. Clin Ther 2009;31 Pt 2:2416–32. doi: 10.1016/j.clinthera.2009.11.020
  4. Weycker D., Hatfield M., Grossman A. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer 2019;19(1):151. doi: 10.1186/s12885-019-5354-5
  5. Elting L.S., Rubenstein E.B., Martin C.G. et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 2001;19(4):1137–46. doi: 10.1200/jco.2001.19.4.1137
  6. Shaw J.L., Nielson C.M., Park J.K. et al. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol 2021;106(5):662–72. doi: 10.1111/ejh.13595
  7. Crawford J., Denduluri N., Patt D. et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer 2020;28(2):925–32. doi: 10.1007/s00520-019-04875-1
  8. Humbrecht C., Kientz D., Gachet C. Platelet transfusion: current challenges. Transfus Clin Biol 2018;25(3):151–64. doi: 10.1016/j.tracli.2018.06.004
  9. Ten Berg M.J., van den Bemt P.M., Shantakumar S. et al. Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy. Drug Saf 2011;34(12):1151–60. doi: 10.2165/11594310-000000000-00000
  10. Cheng H., Hao S., Liu Y. et al. Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation. Blood 2015;126(11):1302–13. doi: 10.1182/blood-2015-01-623645
  11. Johnstone C., Rich S.E. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med 2018;7(2):265–73. doi: 10.21037/apm.2017.11.01
  12. Ker K., Edwards P., Perel P. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054. doi: 10.1136/bmj.e3054
  13. Rebulla P., Finazzi G., Marangoni F. et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997;337(26):1870–5. doi: 10.1056/NEJM199712253372602
  14. Slichter S.J., Kaufman R.M., Assmann S.F. et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362(7):600–13. doi: 10.1056/NEJMoa0904084
  15. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337(26):1861–70. doi: 10.1056/NEJM199712253372601
  16. Tepler I., Elias L., Smith J.W. 2nd. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87(9):3607–14.
  17. Liu N.W., Huang X., Liu S. et al. Elevated BNP caused by recombinant human interleukin-11 treatment in patients with chemotherapy-induced thrombocytopenia. Support Care Cancer 2019;27(11):4293–8. doi: 10.1007/s00520-019-04734-z
  18. Bisi J.E., Sorrentino J.A., Roberts P.J. et al. Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression. Mol Cancer Ther 2016;15(5):783–93. doi: 10.1158/1535-7163.Mct-15-0775
  19. He S., Roberts P.J., Sorrentino J.A. et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med 2017;9(387):eaal3986. doi: 10.1126/scitranslmed.aal3986
  20. Weiss J.M., Csoszi T., Maglakelidze M. et al. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. Ann Oncol 2019;30(10):1613–21. doi: 10.1093/annonc/mdz278
  21. Daniel D., Kuchava V., Bondarenko I. et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled Phase II trial. Int J Cancer 2021;148(10):2557–70. doi: 10.1002/ijc.33453
  22. Hart L.L., Ferrarotto R., Andric Z.G. et al. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther 2021;38(1):350–65. doi: 10.1007/s12325-020-01538-0
  23. Weiss J., Goldschmidt J., Andric Z. et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 2021;22(5):449–60. doi: 10.1016/j.cllc.2021.03.010
  24. Kaushansky K. Thrombopoietin and its receptor in normal and neoplastic hematopoiesis. Thromb J 2016;14(1):40. doi: 10.1186/s12959-016-0095-z
  25. Moskowitz C.H., Hamlin P.A., Gabrilove J. et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol 2007;18(11):1842–50. doi: 10.1093/annonc/mdm341
  26. Vadhan-Raj S., Verschraegen C.F., Bueso-Ramos C. et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000;132(5):364–8. doi: 10.7326/0003-4819-132-5-200003070-00005
  27. Li J., Yang C., Xia Y. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98(12):3241–8. doi: 10.1182/blood.V98.12.3241
  28. Bussel J., Kulasekararaj A., Cooper N. et al. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol 2019;56(4):262–78. doi: 10.1053/j.seminhematol.2019.09.001
  29. Mytych D.T., Park J.K., Kim J. et al. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. Br J Haematol 2020;190(6):923–32. doi: 10.1111/bjh.16658
  30. Townsley D.M., Scheinberg P., Winkler T. et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 2017;376(16):1540–50. doi: 10.1056/NEJMoa1613878
  31. Al-Samkari H., Grace R.F., Kuter D.J. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol 2020;11:2040620720912992. doi: 10.1177/2040620720912992
  32. Demeter J., Istenes I., Fodor A. et al. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. Pathol Oncol Res 2011;17(1):141–3. doi: 10.1007/s12253-010-9276-4
  33. Jacobson A.E., Shah N., Setty B.A. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer 2017;64(8):e26473. doi: 10.1002/pbc.26473
  34. Al-Samkari H., Marshall A.L., Goodarzi K., Kuter D.J. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica 2018;103(4):e169–72. doi: 10.3324/haematol.2017.180166
  35. Parameswaran R., Lunning M., Mantha S. et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer 2014;22(5):1217–22. doi: 10.1007/s00520-013-2074-2
  36. Soff G.A., Miao Y., Bendheim G. et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol 2019;37(31):2892–8. doi: 10.1200/jco.18.01931
  37. Al-Samkari H., Parnes A.D., Goodarzi K. et al. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica 2021;106(4):1148–57. doi: 10.3324/haematol.2020.251900
  38. Kellum A., Jagiello-Gruszfeld A., Bondarenko I.N. et al. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin 2010;26(10):2339–46. doi: 10.1185/03007995.2010.510051
  39. Winer E.S., Safran H., Karaszewska B. et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med 2015;4(1): 16–26. doi: 10.1002/cam4.326
  40. Winer E.S., Safran H., Karaszewska B. et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol 2017;106(6):765–76. doi: 10.1007/s12185-017-2319-9
  41. Bussel J.B., Kuter D.J., Aledort L.M. et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 2014;123(25):3887–94. doi: 10.1182/blood-2013-07-514398
  42. Al-Samkari H., Kolb-Sielecki J., Safina S.Z. et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 2022;9(3):e179–89. doi: 10.1016/S2352-3026(22)00001-1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.